SGCB and small cell lung carcinoma: In the absence of a potent bioavailable sGC inhibitor for in vivo use, we adopted a CRISPR approach to target GUCY1B1 in CDX17P ex vivo and then tested sensitivity to the SCLC standard of care chemotherapy regimen of combined etoposide and cisplatin in vivo (Fig. 5a).